Italia markets closed

Abbott Laboratories (ABT)

NYSE - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
121,69+0,12 (+0,10%)
Al 2:38PM EDT. Mercato aperto.
Accedi per pubblicare un messaggio.
  • J
    Jerry
    $SENS conversation
    $SENS New data released, strong accuracy for 180 day CGM sensor!
    https://www.senseonics.com/investor-relations/news-releases/2021/06-03-2021-210515226

    $DXCM $MDT $ABT
  • s
    stocktargetadvisor
    $ABT conversation
    $ABT
    Target Lowered by Morgan Stanley Overweight USD 140 » USD 126
    Maintains Wells Fargo Overweight USD 137 » USD 125
    Maintains Barclays Overweight USD 150 » USD 125
    Maintains Raymond James Financial Outperform USD 130 » USD 116
    Maintains Citigroup Buy USD 138 » USD 125
  • u
    universe
    $ABT conversation
    $ABT Here is a critically important detail in NYU Langone test, that all the media stories failed to mention..These tests were transported and tested after 1 hr or 2 hr delay. Active CoVID Viral materials on inorganic surfaces decay with time (based on temperature, light exposure, etc.)... Testing after 1 to 2 hrs late is not the same thing, as testing at the Point of Care - right there and then as the Abott ID portable system is designed to do!
    Fake news designed to release just before the Options day to inflict max damage on Abbott's stock and linking it with WH, and questioning the stock rally confidence in getting US up and running again. CNBC and other media should be ashamed to publish without fact checking and being a pawn in Short attack. BUY $ABT!

    +++
    "A total of 101 paired samples collected during 12 hour
    shifts over 3 consecutive days were included. Ninety-three percent of the samples were transported to the laboratory within 1 hour for testing, the remainder within 2 hours. Testing at the point of
    care was not practical. .."
    Link to NYU Langone study

    https://www.biorxiv.org/content/10.1101/2020.05.11.089896v1.full.pdf
  • u
    universe
    $ABT conversation
    $ABT ...great news...Abbott provides updates on ramping up production...shipped 5 million tests already as of Apr 24..which means it will exceed its 5M shipping target for April by 10-20% ...Let's see!

    ID NOW – shipped more than 1 million. currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.

    m2000 – Our large, high-volume laboratory instrument. shipped more than 1.4 million tests. There are approximately 200 m2000 instruments in hospital, academic center and reference labs throughout the U.S.

    Antibody test – Last week, Abbott announced and began shipping a lab-based antibody blood test that helps determine if a person was previously infected with the virus that causes COVID-19.
    Shipped 2.5 million tests to customers. plans to ramp up to 20 million antibody tests in June and beyond, and expand our testing capabilities to our Alinity i lab system.

    https://www.abbott.com/corpnewsroom/product-and-innovation/an-update-on-abbotts-work-on-COVID-19-testing.html
    Abbott began distributing rapid point-of-care COVID-19 tests for our ID NOW system on Tues., March 31. We plan to produce 2 million tests a month by June and to expand beyond that.
    Abbott began distributing rapid point-of-care COVID-19 tests for our ID NOW system on Tues., March 31. We plan to produce 2 million tests a month by June and to expand beyond that.
    www.abbott.com
  • u
    universe
    $ABT conversation
    $ABT...Moody's reconfirms A3 i.e investment grade rating for Abbott with the following comments ...
    ++++++++
    Abbott Laboratories' ("Abbott") A3 rating reflects its significant scale in the global healthcare industry. The company is very well diversified, with four distinct business units -- medical device, pharmaceutical, diagnostics and nutrition. Abbott also benefits from market leading positions in most of its segments. Abbott is also geographically diverse and revenue growth will continue to benefit from its meaningful presence in faster-growing emerging markets. Abbott's ratings reflect its moderate leverage.

    http://www.moodys.com:18000/research/Moodys-announces-completion-of-a-periodic-review-of-ratings-of--PR_422519
  • B
    Brendan
    $CODX conversation
    Co-Diagnostics, a company with no debt, a diverse client base (at least 15 states and 50 countries) phenomenal per-unit profit margins despite its affordable price, the most accurate, innovative, least invasive product within the most in-demand product segment worldwide. Even if somewhere down the line the tests prove to be less than 100% accurate their current price is still far undervalued considering their sales' trajectory based on extrapolating the sales announced in the earnings report, combined with the fact that Abbott Labs $ABT has proven there is still a strong market for inaccurate tests, 1 study showed Abbott's test had a 50% false-negative rate, yet they are still selling that junk in droves. Somehow people still have their doubts, I am currently living my my life as frugally as possible so I can continue spending every cent I can save to buying more shares every time it dips below $17.50. Get in while you can during this gift of an entry point.
  • u
    universe
    $ABT conversation
    $ABT...The WH Administration is sending $11 billion to help States, territories, and tribes meet the testing goals ...Abbott and its 5-minute test is specifically mentioned in the directive...Abbott is in a great position to get a large market share of this $11B additional funding..

    https://www.whitehouse.gov/briefings-statements/united-states-built-worlds-leading-coronavirus-testing-system/
  • B
    Brendan
    $CODX conversation
    People seem to overwhelmingly view $CODX through the lens of its high-ceiling potential, but in my opinion their high-floor is equally as appealing in this uncertain market. I think we can get a much more complete picture of their position through a basic SWOT analysis.

    Let’s start by first looking at Co-Diagnostics' strengths and opportunities. They are a company with no debt, a diverse client base with at least 15 states and 50 countries at the time of their q1 earnings report, phenomenal per-unit profit margins of over 70% in spite of being priced very affordably. Their COVID test that, as it stands, is the most accurate, innovative, and least-invasive test within the most in-demand product segment in the world

    Next, let’s look at $CODX through their threats and weaknesses. Every single negative news article about $CODX I could find concerning their COVID tests revolve around one central idea, the threat of their test found to be anything less than 100% accurate, but all those critics seem to imply the same outcome should this happen, that if the test is anything less than perfect it will cause their test sales to significantly and abruptly diminish to next to nothing. Fortunately for us we have a perfect comparison to see would happens in that scenario through their biggest competitor, $ABT Abbott Labs’ tests, tests which in April were proven to be inaccurate, so inaccurate in fact, that during one mid-April trial the tests were found to give COVID false-negative text results 50% of the time! Despite this fact, you can see through a quick search in google news that they are still currently getting order for those inaccurate tests in mass quantities. So even if $CODX critics' worst case scenario would come to fruition tomorrow, working under the assumption that potential customers of $CODX would react in a similar fashion to the news of Abbott's tests' inaccuracy, would still be in a position to have their demand come close to, if not exceed, their 3 million tests/week capacity. Abbott Labs' example has clearly shown customers will still take a slightly inaccurate test, or in Abbott's case a very inaccurate test, over having no testing capabilities at all, especially when you factor in the added incentive of their appealing price-point.

    If you even somewhat agree with my reasoning of $CODX's tests' inelastic demand extrapolate the sales numbers from their Q1 earnings report and you will get clear picture that this stock is far undervalued. Investment opportunities like this are few and far between. Not only does $CODX have sky-high potential, but they are also have a very understated level of safety when you consider their lack of debt, quality product, and unbelievable and sustainable demand. The window to get in is now, buy with confidence!
  • J
    John
    $SENS conversation
    $SENS 🚀Senseonics🚀 the NEXT BNGO
    ✅Senseonics is a medical device startup company in USA developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease.
    ✅Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.
    ✅The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

    🚨FDA set to approve 180 day CGM system
    🚨🚨BIG INSTITUTIONAL INVESTORS
    George Soros 5% ownership (Soros Fund Management) holds 10mil shares and Roche 16% ownership holds 30mil shares. Biggest ownership at 24% PHC Holdings Corp holds 68mil shares!
    $DXCM $ABT
  • u
    universe
    $ABT conversation
    $ABT
    as you can see Abbott's MMs seem to be influencing the price a bit, and they want to have a strong consolidate base at $94-$96 levels. I can understand as the stock quickly appreciated to $100 level and they want avoid sharp pull backs etc..
    But I think the MMs need to let the stock run a bit and let the market forces do its magic a bit..the stock will attract volume if investors see it is running...it is like a self fulling prophecy.
    Today we had 55% short volume (much more compared to the last few days). This is the another problem that a stagnant price may attract.
    In conclusion, Abbott's MMs - you have done a great job keeping a stable price trajectory of this stock..but you also need to pay close attention to the short sellers.. and let the market momentum do its magic..we should get past $115 in no time!!
  • N
    Nathan
    $ABT conversation
    I've acquired a fairly large stake over the past week. The diabetes treatment companies are a great space. Diabetes affects a larger population every year, and these products are revolutionary. I'll ride both $DXCM and $ABT over the long term and i'm confident I won't regret it. This space laughs at the trade war and economic slowdowns also.
  • u
    universe
    $GILD conversation
    $ABT
    I opened new positions in Abbott Labs . I consider three core pillars of America Back to Work and hence my COVID Portfolio:
    $ABT

    $GILD

    $MRNA

    $ABT
    => TESTING (Abbott labs has the largest lab equipment footprint already in the US... Every hospital, first responder, safe workplace or traveler will need this 5-minute test. Antibody test under development)
    $GILD
    = TREATMENT (most advanced phase 3 FDA trial, result expected anytime. Not a favorite of the wall street analysts, but these are the same geniuses who predicted Tesla stock, COVID stock impact and bottoming of the market accurately.. Gilead is the only company with BOTH => global production capacity and most mature treatment that has already shown results . US DoD has already recommended this treatment for its critical personnel)
    $MRNA
    = VACCINE (most mature candidate..Bill Gates and US Govt invested. Advanced directly to Human Safety trial. WH announcement expected anytime)
    All 3 companies with long-term GLOBAL demand trends!
  • u
    universe
    $ABT conversation
    $ABT
    ...Tomorrow's ER is not about the past qtr, it is about its future. Every analyst will be asking the the mgt on the revenue potential of Abbott's COVID Infection Test and Antibody Test.
    I would imagine every event company (say Disney, NFL, NBA) , travel company (top airlines, hotels), critical workplace (say Amazon Warehouse of the world, hospitals, first responder agencies, government offices, DoD, etc.) putting an order for these tests. Every governor is going to need these machines to open their respective states. Now think about the private sector offices - New York Stock Exchange to Schools to every household in America would want to have the Antibody test done so they can freely live, travel and work. You get the picture --- COVID has fundamentally changed the revenue potential, growth, EBITDA and hence P/E premium multiple of this great company. You are looking at a fundamental NEW great Abbott Labs..like a new Tesla in the car world. new iPhone in the cellphone world. BUY!
  • C
    Covid Kid
    Think about this - WE ARE NOW IN DIRECT COMPETITION W/ $ABT LABS (which saw a $7 jump in share price to $111 a share)...AND OUR PRODUCT IS 60X’S FASTER AND WE HAVE AN INTERNATIONAL DISTRIBUTION CHANNEL ALREADY ESTABLISHED!!!

    Carry on...
  • M
    Mike
    $CRON conversation
    Shorts scared. CRON with $1,576,000,000,000 in cash they could buy many companies and merge with $TLRY. V shape Recovery. The market will go back to new highs. $JNJ has a vaccine using it on an emergency basis. $ABT has 5-minute testing. That story will be destroyed and on to the next.
  • u
    universe
    $ABT conversation
    $ABT..so all the major Retail pharmacies across the US i.e. CVS, Walgreens, Rite Aid are going to use Abbott 5-minute point of care test...it's like selling pickaxes during a gold rush..not to mention Abbott's patent-protected tech and direct-to-consumer footprint almost assuring a complete hold on the market for many years to come!!!
    And guess what other lab tests that beautiful Abbott portable machine can do along with CoVID..Influenza, strep throat, other infectious diseases...this is a revenue game changer for Abbott and pharmacies..traditional labs should be worried..I did not chase Lab Corp at-home mailing test etc. , any test that takes more than 48-hr is useless...etc!
    I bought Abbott and adding to my portfolio...
  • A
    Ape
    Citron. Mkt will recognize that $ABT news is good for $FLDM. More + antigen cases drives testing to the more accurate $FLDM PCR test to confirm. Screening vs Confirmatory $ABT is a good short term solution, the $FLDM only saliva bases assay that can scale..
  • a
    aftab
    Get ready for #ABT tomorrow, their 15 minutes test distributed everywhere and thousands more in few days
  • D
    Dr Cheddar
    $SRNE conversation
    /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its...
    /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its...
    www.prnewswire.com